Is there cross‑reactivity between metamizol (dipyrone) and nonsteroidal anti‑inflammatory drugs (NSAIDs)?

Metamizole Cross-Reactivity with NSAIDs

Metamizole (dipyrone) hypersensitivity reactions are typically drug-specific and do NOT cross-react with other NSAIDs through COX-1 inhibition mechanisms. 1

Mechanism and Classification

Metamizole reactions operate through a distinct immunologic mechanism compared to typical NSAID cross-reactivity:

• Metamizole hypersensitivity is IgE-mediated and drug-specific, not related to arachidonic acid/COX-1 dysfunction that characterizes cross-reactive NSAID reactions 1
• Skin tests demonstrate high positivity rates in metamizole-allergic patients (100% in one series of 6 subjects), confirming specific IgE involvement 1
• Any NSAID, including selective COX-2 inhibitors, may be responsible for metamizole reactions, but this reflects the broad potential for drug-specific reactions rather than cross-reactivity 1

Clinical Evidence

The evidence strongly supports metamizole as a "single NSAID reactor" pattern:

• Metamizole belongs to the pyrazolone derivative class, where positive skin tests and ELISA results were documented in 51 of 53 patients with pyrazolone hypersensitivity 1
• In a large series of 137 metamizole-allergic patients, most (96.4%) developed single NSAID-induced urticaria/angioedema/anaphylaxis (SNIUAA), with 60.6% experiencing anaphylaxis 2
• 97.2% of metamizole-allergic patients tolerated alternative NSAIDs, specifically meloxicam and etoricoxib, demonstrating lack of cross-reactivity 3

Management Algorithm

For patients with confirmed metamizole hypersensitivity:

1. Avoid metamizole permanently - the culprit drug should always be avoided 1

2. Challenge with structurally unrelated NSAIDs to establish safe alternatives:

   • Selective COX-2 inhibitors (celecoxib, etoricoxib) are generally well-tolerated 3
   • NSAIDs from different chemical classes can be safely used 1
   • Direct aspirin challenges should be performed to allow future aspirin use 1

3. Diagnostic approach when needed:

   • Skin testing is the primary diagnostic tool (62% sensitivity in one series) 2
   • Basophil activation testing can be used if skin tests are negative (28% positive rate) 2
   • Drug provocation testing may be required in only 5% of cases 2

Critical Caveats

Important distinctions to avoid mismanagement:

• Do not confuse metamizole reactions with COX-1 inhibitor cross-reactivity syndromes (AERD or NSAID-exacerbated cutaneous disease), which have entirely different mechanisms and management 1
• The reaction is not due to arachidonic acid dysfunction, distinguishing it from cross-reactive NSAID patterns 1
• While rare cases of cross-reactivity in fixed drug eruption have been reported between various NSAIDs 4, this represents a different delayed hypersensitivity mechanism (T-cell mediated) occurring in <5% of NSAID reactions 1

Selective COX-2 inhibitors are the preferred alternative when an NSAID is medically necessary in any NSAID hypersensitivity phenotype, including metamizole allergy 1